Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale
May 20, 2024 07:00 ET
|
Pluri Inc.
New production process will be developed based on Pluri’s proprietary 3D cell expansion technologyHuman breast milk oligosaccharides are known to shape the gut microbiota and thus provide health...
Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment
May 02, 2024 07:00 ET
|
Pluri Inc.
Placental Mucosal Associated Invariant T (MAIT) cells are unique unconventional immune T cells which are particularly suitable for the treatment of solid tumors, a significant unmet medical needMAIT...
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method
April 08, 2024 07:00 ET
|
Pluri Inc.
Pluri’s patent enables mass-scale production of immune cell therapiesNew patented technology is applicable for the expansion of a variety of immune cellsTechnology sets stage for potential immune cell...
Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences
March 28, 2024 07:15 ET
|
Pluri Inc.
HAIFA, Israel, March 28, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote...
Pluri Inc. Announces 1-for-8 Reverse Share Split
March 27, 2024 07:00 ET
|
Pluri Inc.
HAIFA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the “Company"), a leading biotechnology company that transforms cells into solutions, today...
Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report
March 21, 2024 07:00 ET
|
Pluri Inc.
International Coffee Organization (ICO) Market Report published on March 7, 2024 highlights alarming price instability challenging the coffee industryAccording to the report, adverse weather...
Engage with Pluri's Talent: Exciting Conference Appearances Ahead
March 19, 2024 04:00 ET
|
Pluri Inc.
HAIFA, Israel, March 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote...
Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing
March 14, 2024 07:00 ET
|
Pluri Inc.
HAIFA, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions, today...
Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation
March 11, 2024 07:00 ET
|
Pluri Inc.
HAIFA, Israel, March 11, 2024 (GLOBE NEWSWIRE) -- In a strategic move that underscores its innovative edge in the agtech sector, Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company") today...
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
March 06, 2024 07:00 ET
|
Pluri Inc.
HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote...